AGE immunolocalization in diabetic nephropathy versus nondiabetic renal diseasesa
AGE Immunolocalization (%)b | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sclerotic Glomeruli | GBM | Mesangium | TBM | Interstitium | Vessels | |||||||
CML | PENT | CML | PENT | CML | PENT | CML | PENT | CML | PENT | CML | PENT | |
aAGE, advanced glycation end products; FSGS, focal segmental glomerulosclerosis. | ||||||||||||
bExpressed as percentage of cases with any positive immunostaining. | ||||||||||||
cExpressed as percentage of cases with 2+ or 3+ immunostaining. | ||||||||||||
Diabetic nephropathy | 94.4 | 87.8 | 42.3 | 3.9 | 96.2 | 76.9 | 84.6 | 30.8 | 15.4 | 92.3 | 96.2 | 53.9 |
Primary FSGS | 71.4 | 100.0 | 50.0 | 10.0 | 20.0 | 40.0 | 30.0 | 50.0 | 10.0 | 70.0 | 40.0 | 30.0 |
Secondary FSGS | 40.0 | 60.0 | 0.0 | 0.0 | 14.3 | 85.7 | 14.3 | 0.0 | 14.3 | 28.6 | 28.6 | 14.3 |
Hypertensive nephrosclerosis | 100.0 | 71.4 | 42.9 | 0.0 | 28.6 | 28.6 | 85.7 | 28.6 | 42.9 | 57.1 | 100.0 | 85.7 |
Lupus nephritis | 80.0 | 60.0 | 54.5 | 45.5 | 27.3 | 63.6 | 27.3 | 36.4 | 0.0 | 90.9 | 54.5 | 18.2 |
AGE Immunolocalization (%)c | ||||||||||||
Sclerotic Glomeruli | GBM | Mesangium | TBM | Interstitium | Vessels | |||||||
CML | PENT | CML | PENT | CML | PENT | CML | PENT | CML | PENT | CML | PENT | |
Diabetic nephropathy | 77.8 | 55.6 | 18.2 | 3.9 | 30.8 | 30.8 | 53.8 | 11.5 | 3.9 | 61.5 | 80.8 | 19.2 |
Primary FSGS | 14.3 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 30.0 | 10.0 | 30.0 | 30.0 | 10.0 |
Secondary FSGS | 20.0 | 40.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Hypertensive nephrosclerosis | 57.1 | 71.4 | 0.0 | 0.0 | 0.0 | 0.0 | 28.6 | 28.6 | 0.0 | 28.6 | 100.0 | 28.6 |
Lupus nephritis | 60.0 | 40.0 | 9.1 | 27.3 | 9.1 | 18.2 | 0.0 | 18.2 | 0.0 | 27.3 | 18.2 | 9.1 |